Compass Therapeutics Inc. (CMPX)
NASDAQ (CM) NASDAQ (CM) Primary 
Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one complete response, compared to 5.3% ORR for paclitaxel alone, in patients with biliary tract cancer (BTC) treated in the second-line setting. The difference in ORR between the two treatment arms, the primary endpoint of the study, was statistically significant (p=0.031), and all responses have been confirmed by blinded independent central radiology review.
Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: What Does It Mean for the Stock?
Compass Therapeutics, Inc. (CMPX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is Compass Therapeutics, Inc. (CMPX) Stock Outpacing Its Medical Peers This Year?
Here is how Compass Therapeutics, Inc. (CMPX) and Bristol Myers Squibb (BMY) have performed compared to their sector so far this year.
Down -23.46% in 4 Weeks, Here's Why You Should You Buy the Dip in Compass Therapeutics, Inc. (CMPX)
Compass Therapeutics, Inc. (CMPX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
What Makes Compass Therapeutics, Inc. (CMPX) a New Buy Stock
Compass Therapeutics, Inc. (CMPX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: Here's Why
Compass Therapeutics, Inc. (CMPX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
